CD8A and neoplasm: Ovarian cancer is also refractory to treatment, and recent studies have shown that low-dose DAC administration increased NK cell and CD8+ T cell recruitment and prolonged mouse survival in a murine transplantation tumor model of ovarian cancer, while the combination of DAC enhanced the therapeutic efficacy of anti-CTAL-4 treatment, and further studies have found that the combination of DNMTis can enhance the cytotoxic T cell response249.